Although much of what we see on the internet has originated in China, we are starting to see some information from Italy.
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Onder G, Rezza G, Brusaferro S. JAMA. 2020 Mar 23. doi: 10.1001/jama.2020.4683. [Epub ahead of print]
Sadly the death rate seems to be higher than has been noticed in China however as you can see in people over 80 this is high and I now suspect this will become even higher, because as the medical system becomes overloaded, people are be triaged for attempted treatment or to recieve no treatment. It is quite possible that we are heading for this problem in the UK. Therefore, whilst you might feel young and invincible, as you are likely to survive, spare a thought for your mum and dads and grans and grandads that may not be so resilient. So keep your distance from them ,
The are reasons why the reported death rate may be different and some of it it may relate to how the deaths were reported.
There are risk factors for doing badly and 30% had ischemic heart disease, 35.5% had diabetes, 20.3% had active cancer, 24.5% had atrial fibrillation, 6.8% had dementia, and 9.6% had a history of stroke. The mean number of preexisting diseases was 2.7 (SD, 1.6). Overall, only 3 patients (0.8%) had no diseases, 89 (25.1%) had a single disease, 91 (25.6%) had 2 diseases, and 172 (48.5%) had 3 or more underlying diseases. The presence of these comorbidities might have increased the risk of mortality independent of COVID-19 infection.
Obviously we are concerned about people on DMT and so keep those stories coming in #MSCOVID19. We have had a case of someone in London 3 weeks post cycle 2 of alemtuzumab, who had mild symptoms for 2 weeks and recovered, so you can’t get much more immunosuppressed than that.
Looking at a case report of the animal and human data, it seems to me that the virus is cleared before there is a significant antibody response. The antibody response will, however, protect you from possible re-infection in the future. This takes a few weeks to kick in. I suspect the innate nervous system is of central importance to virus killing. Most of the high efficacy MS drugs do not really target the monocytes or the neutrophils and this could be a good thing.